Issue link: http://clhia.uberflip.com/i/406567
15 THEREFORE, THE CLHIA RECOMMENDS THAT: • THE BOARD OF THE PMPRB BE REQUIRED TO INCLUDE PRIVATE INSURER REPRESENTATION TO ENSURE THAT THEIR PERSPECTIVES ARE CONSIDERED IN THE OVERALL OPERATIONS OF THE PMPRB GOING FORWARD. b.2 Provincial Listing Process Once a drug is approved for sale in Canada by Health Canada and its reference price has been established by the PMPRB, the provinces, collectively, conduct a "value for money" assessment of new drugs as a key step in the decision on whether or not to list the new drug on the provincial formulary. There are essentially three processes as set out below. 1. NON-CANCER DRUGS (COMMON DRUG REVIEW - CDR) The CDR is jointly funded by all provinces, except for Quebec, and reviews all non-cancer drugs. This review can take between six and eight months. The CDR does a cost-benefit analysis and recommendations for public funding are based on effectiveness and cost considerations. The CDR recommends which new non-cancer drugs should be covered under publicly funded drug benefit plans in Canada. 2. THE PAN-CANADIAN ONCOLOGY DRUG REVIEW (PCODR) The pCODR is jointly funded by all provinces, except for Quebec, and reviews all cancer drugs. The review takes between five and eight months to complete. The pCODR review does a cost-benefit analysis and recommendations for public funding are based on effectiveness and cost considerations. The pCODR recommends which new cancer drugs should be covered under publicly funded drug benefit plans in Canada.